Clinical trial
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects…
NCT00144131 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00144131 |
|---|---|
| Title | Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy |
| Official title | Flexibility: A Study to Assess the Impact of Once Per Cycle Correction and Maintenance Dosing of Darbepoetin Alfa in Subjects With Non-Myeloid Malignancies With Anemia Due to Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Cancer |
| Intervention type | Drug |
| Interventions | Aranesp® |
| Enrollment | 750 |
| Start date | Aug 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | May 24, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: